March 2023

実臨床での関節リウマチに用いる生物製剤および分子標的合成抗リウマチ薬の安全性: ARTIS プログラムからのデータ

Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762

Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.

Keywords:

RAにおけるbDMARDsと比較したバリシチニブと トファシチニブの有効性: スウェーデンのナショナル レジストリコホートを用いた結果

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068

Data from the Swedish Rheumatology Quality Register and Swedish Registries, show a higher treatment retention and overall equivalent or better treatment response on baricitinib, compared with bDMARDs or tofacitinib, but no statistically significant differences between tofacitinib and bDMARDs.In this largest population-based study to date, comparing RA patients initiating baricitinib, tofacitinib or bDMARDs, Barbulescu, et al. help to fill some of the current knowledge gaps surrounding the effica...

Keywords: